SCHOTT Pharma AG & Co. KGaA : Strong Q1 earnings above our estimates and significantly above consensus – FY 2024 outlook confirmed
>On track to meet FY 2024 guidance - Schott Pharma released a strong set of Q1 results. Revenues of € 232m (y-o-y +3%) were 1% below our estimates and 3% above consensus (Vara). Group EBITDA came in at € 73m (+15%), 4% higher than our estimate of € 70m and 13.5% above consensus (€ 64m). Based on the strong Q1 2024 results, SCHOTT Pharma confirmed its guidance: organic revenue growth of 9% to 11% (we are at 9.5%) at cc and an EBITDA margin approximately at the prior ye...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.